Relationship of SLCO1B1 and ABCB1 gene polymorphisms with clinical variants of methotrexate toxicity in pediatric acute lymphoblastic leukemia therapy

Background. Despite the significant clinical efficacy of current treatment protocols for acute lymphoblastic leukemia (ALL) in children, high-dose methotrexate demonstrates significant interindividual variability in drug toxicity and disease outcomes due to polymorphisms of drug transporter genes and genes responsible for cytostatic metabolism, which makes pharmacogenetic studies increasingly relevant.

Aim. To evaluate the association of ABCB1 (C3435T rs1045642, rs1128503, rs2032582, rs4148738), SLCO1B1 T521C rs4149056 gene polymorphisms with the main types of methotrexate toxicity and the onset of clinical events (death, recurrence, progression) during the treatment of childhood ALL.

Materials and methods. The study enrolled 103 patients diagnosed with ALL who received therapy according to BFM group protocols (2002/2009), using high-dose (2000 and 5000 mg/m²) methotrexate. Laboratory methods using NCI toxicity scales (CTCAE v5.0 2018) were used to assess adverse reactions. Real-time polymerase chain reaction method was used to study ABCB1 and SLCO1B1 gene polymorphisms. The study material was peripheral blood. Material was sampled once, regardless of the duration of methotrexate therapy. SPSS Statistics 21.0 software was used for statistical processing of the results. Analysis of associations was performed using the χ2 criterion and Fisher’s exact test.

Results. Development of infectious complications, oropharyngeal mucositis, delayed MTX elimination, events were significantly associated with polymorphisms of the studied genes: SLCO1B1 T521C rs4149056, ABCB1 rs4148738, ABCB1 rs1128503, which correlates with the data of world scientific literature.

Conclusion. Determination of polymorphisms of genes responsible for the transport and metabolism of methotrexate is a promising and dynamically developing area of clinical oncology.

1. Howlader N., Noone A., Krapcho M. et al. SEER cancer statistics review, 1975–2014. National Cancer Institute, 2016. Available at: https://seer.cancer.gov/csr/1975_2014/. Accessed 24 Apr. 2018.

2. Shervashidze M.A., Valiev T.T., Tupitsyn N.N. Prospects for evaluation of the minimal residual disease in the post-induction period in pediatric B-precursor acute lymphoblastic leukemia. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2020;7(2):15–22. (In Russ.) DOI: 10.21682/2311-1267-2020-7-2-15-22

3. Terwilliger T., Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017;7(6):e577. DOI: 10.1038/bcj.2017.53

4. Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013;381(9881):1943–55. DOI: 10.1016/S0140-6736(12)62187-4

5. Hilden J.M., Dinndorf P.A., Meerbaum S.O. et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006;108(2):441–51. DOI: 10.1182/blood-2005-07-3011

6. Kotecha R.S., Gottardo N.G., Kees U.R., Cole C.H. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J 2014;4(4):e200. DOI: 10.1038/bcj.2014.17

7. Termuhlen A.M., Smith L.M., Perkins S.L. et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol 2013;162(6):792–801. DOI: 10.1111/bjh.12460

8. Howard S.C., McCormick J., Pui C.H. et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016;21(12):1471–82. DOI: 10.1634/theoncologist.2015-0164

9. Beechinor R.J., Thompson P.A., Hwang M.F. et al. The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children’s Oncology Group. Clin Pharmacokinet 2019;58(7):899–910. DOI: 10.1007/s40262-018-00734-0

10. Lopez-Lopez E., Autry R.J., Smith C. et al. Pharmacogenomics of intracellular methotrexate polyglutamates in patients’ leukemia cells in vivo. J Clin Invest 2020;130(12):6600–15. DOI: 10.1172/JCI140797

11. Shen D.D., Azarnoff D.L. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3(1):1–13. DOI: 10.2165/00003088-197803010-00001

12. Ramsey L.B., Panetta J.C., Smith C. et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013;121(6):898–904. DOI: 10.1182/blood-2012-08-452839

13. Linskey D.W., English J.D., Perry D.A. et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics 2020;30(9):208–11. DOI: 10.1097/FPC.0000000000000412

14. Van de Steeg E., van Esch A., Wagenaar E. et al. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 2013;19(4):821–32. DOI: 10.1158/1078-0432.CCR-12-2080

15. Ramsey L.B., Bruun G.H., Yang W. et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012;22(1):1–8. DOI: 10.1101/gr.129668.111

16. Rask C., Albertioni F., Bentzen S.M. et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia – a logistic regression analysis. Acta Oncol 1998;37(3):277–84. DOI: 10.1080/028418698429586

17. Mikkelsen T.S., Thorn C.F., Yang J.J. et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011;21(10):679–86. DOI: 10.1097/FPC.0b013e328343dd93

18. Borst L., Buchard A., Rosthøj S. et al. Gene dose effects of GSTM1, GSTT1 and GSTP1 polymorphisms on outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2012;34(1):38–42. DOI: 10.1097/MPH.0b013e3182346cdd

19. Uhlén M., Fagerberg L., Hallström B.M. et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347(6220):1260419. DOI: 10.1126/science.1260419

20. Kato T., Hamada A., Mori S., Saito H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2012;27(2):192–9. DOI: 10.2133/dmpk.dmpk-11-rg-066

21. Gregers J., Gréen H., Christensen I.J. et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J 2015; 15(4):372–9. DOI: 10.1038/tpj.2014.81

22. Liu Y., Yin Y., Sheng Q. et al. Association of ABCC2 – 24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One 2014;9(1):e82681 DOI: 10.1371/journal.pone.0082681